Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?

被引:10
|
作者
Tachibana, Masahiro [1 ]
Yonemoto, Yukio [1 ]
Okamura, Koichi [1 ]
Suto, Takahito [1 ]
Sakane, Hideo [1 ]
Kaneko, Tetsuya [1 ]
Dam, Trang Thuy [1 ,2 ,3 ]
Okura, Chisa [1 ]
Tajika, Tsuyoshi [1 ]
Tsushima, Yoshito [3 ,4 ]
Chikuda, Hirotaka [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Orthopaed Surg, Showa Machi 3-39-15, Maebashi, Gunma 3718511, Japan
[2] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol & Nucl Med, Showa Machi 3-39-15, Maebashi, Gunma 3718511, Japan
[3] Bach Mai Hosp, Radiol Ctr, Hanoi, Vietnam
[4] Gunma Univ Initiat Adv Res GIAR, Res Program Diagnost & Mol Imaging, Div Integrated Oncol Res, Maebashi, Gunma, Japan
关键词
Periodontitis; FDG-PET; CT; Biologic therapy; Rheumatoid arthritis; Treatment response; LARGE-JOINT DESTRUCTION; F-18-FDG ACCUMULATION; DISEASE; ASSOCIATION; IMMUNOTHERAPY; INFLAMMATION; ANTIBODIES; PET/CT;
D O I
10.1186/s13075-020-02269-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Rheumatoid arthritis (RA) and periodontitis (PD) have been suggested to share many clinical and pathological features. However, few reports have investigated the relationship between the degree of PD and the treatment response to RA. This study aimed to examine the relationship between the extent of PD and the treatment response to biologics in RA patients using FDG-PET/CT. Methods Sixty RA patients (male,n = 14; female,n = 46; average age, 58.3 years) treated with biologic agents were included in this study. FDG-PET/CT was performed at baseline and 6 months after the initiation of biological therapy. The maximum standardized uptake value (SUVmax) was used as a representative value for the assessment of the FDG uptake in periodontal tissue and joints including the bilateral shoulders, elbows, wrists, hip, knees, and ankle joints. The Disease Activity Score (DAS) 28-CRP and the following clinical parameters were assessed: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-cyclic citrullinated peptide antibody (ACPA), rheumatoid factor (RF), and matrix metalloproteinase 3 (MMP-3). The relationship between the treatment response of RA and the baseline SUVmax of the periodontal tissue was evaluated. Results The baseline periodontal SUVmax was related to patient age (r = 0.302,p = 0.009) and the ACPA level (r = 0.265,p = 0.025). The DAS28-CRP, CRP, ESR, MMP-3, and joint SUVmax values were significantly decreased after 6 months of biological therapy. However, the mean periodontal SUVmax, ACPA, and RF showed no significant changes after treatment. There was a significantly negative correlation between the baseline periodontal SUVmax and the treatment response of DAS28-CRP (r = - 0.369,p = 0.004). Conclusion There was a negative correlation between the extent of PD at baseline and the treatment response of RA patients who received biological therapy. The evaluation of the periodontal condition is considered to be an essential part for the management of RA.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years
    Visman, Ingrid M.
    Boers, Maarten
    Vedder, Daisy
    Twisk, Jos W. R.
    Nurmohamed, Michael T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08) : 1196 - 1197
  • [42] Rheumatoid Arthritis: Genetic Tests predict the Chance of Treatment Success with Biologics Reducing Treatment Costs
    Voormann, A.
    JOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN, 2019, 26 (02): : 63 - 63
  • [43] Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis
    Deodhar, Atul A.
    Bitman, Bojena
    Yang, Yue
    Collier, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [44] ETANERCEPT TREATMENT DOES NOT ADVERSELY AFFECT TRADITIONAL CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Deodhar, A.
    Bitman, B.
    Yang, Y.
    Collier, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 224 - 224
  • [45] Treatment response to biologics agents in psoriatic patients with or not psoriatic arthritis
    Masouri, S.
    Moustou, A. -E.
    Papoutsaki, M.
    Stefanaki, I.
    Sachlas, A.
    Vergou, T.
    Antoniou, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 93 - 93
  • [46] Biomarkers and treatment response in patients with rheumatoid arthritis
    Senolt, L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 : 61 - 61
  • [47] Gut microbiome and treatment response in rheumatoid arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (02): : E100 - E100
  • [48] Prediction of Response to Targeted Treatment in Rheumatoid Arthritis
    Wijbrandts, C. A.
    Tak, P. P.
    MAYO CLINIC PROCEEDINGS, 2017, 92 (07) : 1129 - 1143
  • [49] Biomarkers for treatment response in rheumatoid arthritis: Where are they?
    Zhao, Sizheng Steven
    Moots, Robert J.
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2020, 1 (01): : 1 - 3
  • [50] Genetic markers of treatment response in rheumatoid arthritis
    Wesoly J.
    Wessels J.A.M.
    Guchelaar H.-J.
    Huizinga T.W.J.
    Current Rheumatology Reports, 2006, 8 (5) : 369 - 377